TRCT
GBIO

Tower Research Capital (TRC)’s Generation Bio GBIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,595
Closed -$5.11K – 5358
2025
Q2 		$5.11K Sell
1,595
-496
-24% -$1.91K ﹤0.01% 4226
2025
Q1 		$8.47K Buy
2,091
+1,061
+103% +$7.45K ﹤0.01% 3889
2024
Q4 		$10.9K Buy
1,030
+655
+175% +$11.7K ﹤0.01% 3764
2024
Q3 		$9.26K Sell
375
-970
-72% -$25.7K ﹤0.01% 3885
2024
Q2 		$37.9K Buy
1,345
+887
+194% +$28.8K ﹤0.01% 3308
2024
Q1 		$18.7K Sell
458
-414
-47% -$9.75K ﹤0.01% 3060
2023
Q4 		$14.4K Buy
872
+9
+1% +$157 ﹤0.01% 3889
2023
Q3 		$32.7K Buy
863
+456
+112% +$21.6K ﹤0.01% 2952
2023
Q2 		$22.4K Buy
407
+16
+4% +$734 ﹤0.01% 3284
2023
Q1 		$17K Buy
391
+61
+18% +$2.95K ﹤0.01% 3630
2022
Q4 		$13K Sell
330
-288
-47% -$15.1K ﹤0.01% 3603
2022
Q3 		$33K Sell
618
-456
-42% -$28.5K ﹤0.01% 3522
2022
Q2 		$70K Buy
1,074
+961
+850% +$62.8K ﹤0.01% 2579
2022
Q1 		$8K Sell
113
-423
-79% -$24.5K ﹤0.01% 4583
2021
Q4 		$38K Buy
536
+85
+19% +$14.8K ﹤0.01% 3002
2021
Q3 		$113K Buy
451
+171
+61% +$40.9K ﹤0.01% 2293
2021
Q2 		$75K Buy
280
+102
+57% +$30.5K ﹤0.01% 2667
2021
Q1 		$51K Buy
178
+21
+13% +$6.72K ﹤0.01% 3108
2020
Q4 		$44K Sell
157
-78
-33% -$25K ﹤0.01% 3228
2020
Q3 		$72K Buy
+235
New +$56.2K ﹤0.01% 3374

Other funds holding GBIO

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Tower Research Capital (TRC)'s GBIO Position: Q3 2025 in Review

Tower Research Capital (TRC) sold out of Generation Bio (GBIO) in Q3 2025, closing a stake of 1,595 shares — an estimated $5.11K sold.

Tower Research Capital (TRC) first reported a position in GBIO in Q3 2020 and held it in 20 quarters. The position peaked at $113K in Q3 2021. 41 funds tracked by Wall St. Rank hold GBIO as of Q3 2025.

  • Tower Research Capital (TRC) reported no remaining Generation Bio position as of Q3 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,595 Generation Bio shares in Q3 2025, an estimated $5.11K.
  • Tower Research Capital (TRC) first reported a position in Generation Bio in Q3 2020 and held it in 20 quarters.
  • Tower Research Capital (TRC)'s Generation Bio position peaked at $113K in Q3 2021.
  • 41 funds tracked by Wall St. Rank held Generation Bio as of Q3 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.